by Affan Faisal  , Zain Tariq  , Harshini Maheswaran  and Maheswaran Pitchaimuthu

Received: 23 April 2026;  Published: 17 August 2026;  doi: 10.21926/obm.transplant.2603273

Liver transplantation is the definitive treatment for end-stage liver disease, acute liver failure, and selected hepatic malignancies, but its success is limited by a persistent shortage of suitable donor organs. This has driven increased use of extended criteria donors (ECDs), including steatotic and donation after circulatory death (DCD) grafts, which are more susceptible to preservation injury and often inadequately supported by traditional static cold storage (SCS). Machine perfusion (MP) ha [...]

by Vikash Chandra Mishra  , Dinesh Chandra  and Vimarsh Raina

Received: 24 March 2026;  Published: 30 July 2026;  doi: 10.21926/obm.transplant.2603272

Hematopoietic stem cell transplantation (HSCT) offers a potentially curative option for a range of malignant and non-malignant hematological disorders. However, only approximately 25-30% of patients have access to a human leukocyte antigen (HLA)-matched related donor (MRD), necessitating alternative donor approaches, including matched unrelated donor (MUD) and haploidentical transplantation. Although advances in haploidentical HSCT have substantially improved donor availability, MUD HSCT continu [...]